NeuBase Therapeutics (NBSE) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free NBSE Stock Alerts $0.38 0.00 (0.00%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:11 PM | bizjournals.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 11, 2024 | americanbankingnews.comNeuBase Therapeutics, Inc. (NASDAQ:NBSE) Short Interest Down 36.3% in AprilMay 6, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekApril 6, 2024 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comNeuBase Therapeutics Announces Receipt of Notice from NasdaqMarch 27, 2024 | msn.comWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 26, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | investorplace.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 25, 2024 | bizjournals.comNeuBase Therapeutics sets shareholder meeting on dissolution planFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics IncFebruary 20, 2024 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE)January 20, 2024 | ca.finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)December 22, 2023 | bizjournals.comCMU halts licensing agreement with NeuBase TherapeuticsNovember 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 02:11 PM with a stated reason of "LULD pause." Trading set to resume at 02:11 PM. November 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 01:11 PM with a stated reason of "LULD pause." Trading set to resume at 01:11 PM. November 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 01:11 PM with a stated reason of "LULD pause."November 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 01:11 PM with a stated reason of "LULD pause." Trading set to resume at 01:11 PM. November 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 10:11 AM with a stated reason of "LULD pause."November 30, 2023 | marketbeat.comTrading was temporarily halted for "NBSE" at 10:11 AM with a stated reason of "LULD pause."November 27, 2023 | finance.yahoo.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 6, 2023 | morningstar.comNeuBase Therapeutics Inc NBSEOctober 6, 2023 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE.MX)September 12, 2023 | benzinga.comMassive Insider Trade At NeuBase TherapeuticsSeptember 12, 2023 | msn.comNeuBase falls after largest shareholder disposes of part stakeSeptember 8, 2023 | finance.yahoo.comNeuBase Therapeutics Issues Statement Regarding Filing By ShareholderSeptember 6, 2023 | markets.businessinsider.comWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?August 16, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)August 6, 2023 | fool.comNeuBase Therapeutics (NASDAQ: NBSE)August 3, 2023 | finance.yahoo.comNeuBase Therapeutics to Explore Strategic AlternativesAugust 1, 2023 | bizjournals.comPittsburgh biotech firm amends stock incentive planJune 30, 2023 | finance.yahoo.comNeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 29, 2023 | finance.yahoo.comNeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to RedosingJune 28, 2023 | finance.yahoo.comNeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 14, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Announces 1-for-20 Reverse Stock SplitJune 14, 2023 | msn.comNeuBase Therapeutics to undertake 1-for-20 reverse share splitJune 14, 2023 | finance.yahoo.comNeuBase Announces 1-for-20 Reverse Stock SplitMay 24, 2023 | finance.yahoo.comNeuBase to Participate in Jefferies Healthcare ConferenceMay 22, 2023 | msn.comNeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene EditingMay 22, 2023 | finance.yahoo.comNeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™May 16, 2023 | finance.yahoo.comNeuBase Announces Formation of Gene Editing Advisory BoardMay 12, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Reports Business Update and Financial Results for the First Quarter of 2023May 11, 2023 | msn.comNeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02May 11, 2023 | finance.yahoo.comNeuBase Reports Business Update and Financial Results for the First Quarter of 2023May 2, 2023 | finance.yahoo.comNeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingApril 20, 2023 | msn.comWhy MIND Technology Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving PremarketMarch 27, 2023 | msn.comWhy Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving PremarketFebruary 15, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023February 14, 2023 | finance.yahoo.comNeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023December 29, 2022 | finance.yahoo.comNeuBase Therapeutics selling stake in company to New York investment firm Alumni CapitalDecember 21, 2022 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022 Get NeuBase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… NBSE Media Mentions By Week NBSE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBSE News Sentiment▼0.970.55▲Average Medical News Sentiment NBSE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBSE Articles This Week▼40▲NBSE Articles Average Week Get NeuBase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INM News Today LSDI News Today PBLA News Today ATNF News Today BDRX News Today GRI News Today PRFX News Today ALLR News Today QLGN News Today PXMD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBSE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
